ClinicalTrials.gg
DrugRead study by study

Cobimetinib clinical trials

Also written Cotellic, GDC-0973 and XL518.

studies test it
94
open now
14
in phase 3
8
first study started
2007
ClinicalTrials.gov finds 122 studies for cobimetinib. How that becomes 94 here

Every study that search finds has been read, to see whether and how it gives cobimetinib. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 122Found by its intervention search · See all 122 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 113 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. 122Give cobimetinib to participants
  3. −5Observe patients on it, or give it outside a trial
  4. −23Give it beside what is tested
  5. 94Test it: the count on this site

Get an email when these change. Save the cobimetinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
10 Nov 2015 · COTELLIC · NDA 206192 (FDA, Drugs@FDA)
European Union
20 Nov 2015 · Cotellic · EMEA/H/C/003960 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Cobimetinib
76
MEK Inhibitor GDC-0973
13

Brand

Cotellic
31

Development codes

GDC-0973
25
XL518
18
RO5514041
7

In one entry with another drug

Given together, or one or the other

Vemurafenib and Cobimetinib
3

Studies by the year they started

94 studies that test it; most in 2017 (16)

Studies that test cobimetinib, by start year
YearStudies
20071
20091
20102
20112
20122
20135
20145
20159
20169
201716
201812
20194
20207
20219
20222
20235
20241
20251
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
35
Phase 2
61
Phase 3
8
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 38 · Other 56

Hoffmann-La Roche (21) · Genentech, Inc. (15) · OHSU Knight Cancer Institute (4) · National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (3) · Fondazione Melanoma Onlus (2) · Hanmi Pharmaceutical Company Limited (2) · Peter MacCallum Cancer Centre, Australia (2)

Often tested with

Tested in the same studies.

Atezolizumab (39) · Vemurafenib (25) · Alectinib (11) · Trastuzumab (10) · Pertuzumab (10) · Bevacizumab (9) · Olaparib (8) · Entrectinib (7)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

New treatments tested with it · 8 most studied

New when their studies opened, with cobimetinib beside them; studies of each.

Reaching primary completion within a year · 7, 1 in phase 3

Studies that test cobimetinib, phase 3 first.

Studies

Open first, then newest update. How each study uses cobimetinib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 94

See all 94 studies that test cobimetinib →

Tested on its own · 11 — no other medicine in its arm
Tested with established drugs · 8 — they are given beside it
Tested in a combination · 75 — another drug in the study is under test too

Showing 20 of 75. See all 75 →

Beside an established treatment under test · 5 — an approved drug, surgery or radiation is what the study tests

Tested with cobimetinib: atezolizumab 2 · Bevacizumab 1

Beside a new treatment under test · 10 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with cobimetinib: Nivolumab 2 · pelcitoclax 1 · XL 888 1 · ifebemtinib 1 · LY3022855 1 · atezolizumab 1 · Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011 1 · ABM-1310 1

Beside supportive care · 4 — a supportive treatment or test is studied
One option of several · 4 — a test or a strategy chooses among drugs
Observed · 5 — patients on it are followed, or it is given outside a trial

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call cobimetinib · ClinicalTrials.gg INT006122

  • MeSH (NLM) C574276cobimetinibOne source NLM
  • UNII (FDA) ER29L26N1XCOBIMETINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1722365Confirmed FDA, Wikidata
  • Wikidata Q15708292cobimetinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C68923CobimetinibOne source FDA
  • DrugBank DB05239One source Wikidata

Also registered as cobimetinib fumarate (UNII 6EXI96H8SV · RxNorm 1722380).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion